Andrew J. Murphy, EVP Research at REGENERON PHARMACEUTICALS, INC. (REGN), sold 23,300 shares at $669.60 ($15.4M) on 2021-12-10, disclosed to the SEC on 2021-12-10.
Open-market sale of $15.4M REGN by EVP Research. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $657.11 | 9,378 | $6.2M | 39.9% |
| 2 | $657.61 | 399 | $262K | 1.7% |
| 3 | $657.61 | 399 | $262K | 1.7% |
| 4 | $658.78 | 330 | $217K | 1.4% |
| 5 | $658.78 | 330 | $217K | 1.4% |
| 6 | $659.29 | 370 |
| $244K |
| 1.6% |
| 7 | $659.29 | 370 | $244K | 1.6% |
| 8 | $660.45 | 4 | $3K | 0.0% |
| 9 | $661.57 | 282 | $187K | 1.2% |
| 10 | $661.57 | 282 | $187K | 1.2% |
| 11 | $662.36 | 354 | $234K | 1.5% |
| 12 | $662.36 | 354 | $234K | 1.5% |
| 13 | $663.61 | 272 | $181K | 1.2% |
| 14 | $663.61 | 272 | $181K | 1.2% |
| 15 | $664.28 | 158 | $105K | 0.7% |
| 16 | $664.28 | 158 | $105K | 0.7% |
| 17 | $665.29 | 404 | $269K | 1.7% |
| 18 | $665.29 | 404 | $269K | 1.7% |
| 19 | $666.40 | 384 | $256K | 1.7% |
| 20 | $666.40 | 384 | $256K | 1.7% |
| 21 | $667.50 | 280 | $187K | 1.2% |
| 22 | $668.42 | 1,738 | $1.2M | 7.5% |
| 23 | $668.42 | 1,738 | $1.2M | 7.5% |
| 24 | $669.60 | 1,018 | $682K | 4.4% |
| 25 | $669.60 | 1,018 | $682K | 4.4% |
| 26 | $670.68 | 872 | $585K | 3.8% |
| 27 | $670.68 | 872 | $585K | 3.8% |
| 28 | $671.33 | 219 | $147K | 1.0% |
| 29 | $671.33 | 219 | $147K | 1.0% |
| 30 | $672.30 | 38 | $26K | 0.2% |
| Total | $662.56 avg | 23,300 | $15.4M | 100% |
| Filing → |
| REGN | SELL | 2024-03-15 | $11.0M | — | Filing → |
| REGN | SELL | 2023-12-06 | $10.6M | — | Filing → |
| REGN | SELL | 2023-11-15 | $10.3M | — | Filing → |